Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599188 | 0.82 | KDM4E (0.54) | TRPV1LMNASLC40A1KDM4EMAPT | |
| SCHEMBL19699467 | 0.82 | LMNA (0.63) | TRPV1LMNAKDM4EMAPT | |
| SCHEMBL171696 | 0.80 | KDM4E (0.62) | TP53MDM4LMNACETPKDM4E | |
| SCHEMBL19977097 | 0.80 | CYP2C19 (0.48) | TRPV1LMNAKDM4EMAPT | |
| SCHEMBL11737069 | 0.79 | MDM4 (0.63) | TRPV1TP53MDM4LMNACETP | |
| SCHEMBL17778730 | 0.78 | TRPV1 (0.50) | TRPV1KDM4EMAPTCASP1CASP7 | |
| SCHEMBL12284605 | 0.76 | TP53 (0.59) | TP53MDM4LMNACETPSLC40A1 | |
| SCHEMBL26885010 | 0.74 | TRPV1 (0.54) | TRPV1TP53MDM4LMNACETP | |
| SCHEMBL26885018 | 0.74 | RAB9A (0.51) | TRPV1TP53MDM4LMNACETP | |
| SCHEMBL26885106 | 0.74 | TRPV1 (0.50) | TRPV1TP53MDM4LMNACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV1 4032/4885TP53 350/4885MDM4 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.